For the treatment of cardiac arrhythmias, the active ingredient can also be used in children and adolescents; while in very young children - ai appropriate dosages and in the right pharmaceutical form - the active ingredient is used for the treatment of hemangioma.
Currently (February 2021), in Italy, propranolol is available in two medicines with the trade name Inderal® (tablets for oral use) and Hemangiol® (oral solution, for use in very young children from 5 weeks to 5 months of life) .
;Furthermore, propranolol in tablets is also indicated in adults, adolescents and children for the control of cardiac arrhythmia.
The propranolol in the form of an oral solution, on the other hand, it is indicated in the treatment of hemangioma in very young children - aged between 5 weeks and 5 months - when:
- Localization and / or extent of lesions pose a threat to life or function;
- The hemangioma is ulcerated and accompanied by pain and / or does not respond to normal medication interventions;
- There is a risk of permanent scarring or deformation.
Furthermore, it is important to know that during treatment with propranolol:
- You may experience a reduction in heartbeat;
- Occasionally, low blood sugar levels (hypoglycaemia) may occur.
